Pancreatic Cell News

Pancreatic Cell News is an online resource providing updates on the latest pancreatitis, diabetes, and pancreatic cancer research.

Reduced Circulating Sphingolipids and CERS2 Activity Are Linked to T2D Risk and Impaired Insulin Secretion

[Science Advances] Researchers examined whole-body ceramide synthase 2 (Cers2) knockout and rs267738 knock-in mice. Both models exhibited glucose intolerance and impaired insulin secretion in vivo. Islets isolated from these models also demonstrated reduced β cell function, as shown by decreased insulin secretion ex vivo.

DOC2b Enrichment Mitigates Proinflammatory Cytokine-Induced CXCL10 Expression by Attenuating IKKβ and STAT-1 Signaling in Human Islets

[Metabolism Clinical and Experimental] Investigators applied biochemical studies, qPCR, proteomics, and immuno-confocal microscopy to determine the underlying protective mechanisms of double C 2 like domain beta (DOC2b) in β-cells.

Pancreatic Cancer-Derived Extracellular Vesicles Remodel the Tumor Microenvironment and Enhance Chemoresistance by Delivering KRASG12D Protein to Cancer-Associated Fibroblasts

[Molecular Therapy] Researchers detected KRASG12D protein in cancer-associated fibroblasts (CAFs) from clinical samples of PDAC. In vitro experiments demonstrated that KRASG12D protein in CAFs was not expressed from its own mutant gene but was derived from the ingestion of tumor cell-derived extracellular vesicles.

Multiomic Quantification of the KRAS Mutation Dosage Improves the Preoperative Prediction of Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma

[Experimental & Molecular Medicine] Scientists evaluated the prognostic value of the dosage of the KRAS G12 mutation, a key PDAC variant, and investigated the biological mechanism of the prognosis associated with the dosage of the KRAS G12 mutation.

The Frontiers of Knowledge Award Goes to the Researchers Who Laid the Biological Foundations for Revolutionary New Treatments in Diabetes and Obesity

[BBVA Foundation] The BBVA Foundation has honored four researchers with the Frontiers of Knowledge Award for their groundbreaking work in establishing the biological foundations for a new class of drugs. These drugs are highly effective in treating type 2 diabetes, promoting significant weight loss in obese individuals, and reducing their risk of cardiovascular issues.

Developmental Beta-Cell Death Orchestrates the Islet’s Inflammatory Milieu by Regulating Immune System Crosstalk

[EMBO Journal] Using a genetic model of caspase inhibition in beta cells coupled with mathematical modeling, scientist discovered an onset of beta-cell death in juvenile zebrafish, which regulated beta-cell mass.

CREB3L1 Facilitates Pancreatic Tumor Progression and Reprograms Intratumoral Tumor-Associated Macrophages to Shape an Immunotherapy-Resistance Microenvironment

[Journal For Immunotherapy of Cancer] Functionally, researchers confirmed cyclic AMP response element binding protein 3-like protein 1 (CREB3L1) contributing to PDAC malignant progression including growth and metastasis by multiple in vitro and in vivo models.

MICAL2 Promotes Pancreatic Cancer Growth and Metastasis

[Cancer Research] The authors highlighted the multiple ways in which MICAL2 impacted PDAC biology and provided a foundation for future investigations into the potential of targeting MICAL2 for therapeutic intervention.

The Growing Range of Complications of Diabetes Mellitus

[Trends In Endocrinology and Metabolism] A common pathophysiological characteristic in type 2 diabetes mellitus is the presence of insulin resistance and chronic low-grade inflammation which can damage the liver, brain, and muscles, and increase the risk of some cancers.

Fellowship Fuels Research on Pancreatic Cancer

[University of Auckland] Dr. Howe Mao has been awarded a $260,000 Clinical Research Training Fellowship to improve molecular understanding of pancreatic cancer.

Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival

[Nature Medicine] Investigators characterized the genomic and clinical correlates of outcomes in PDAC. They showed that a genomic subtype of KRAS wild-type tumors was associated with early disease onset, distinct somatic and germline features, and significantly better overall survival.

Effect and Safety of Sivelestat on Acute Severe Pancreatitis with Systemic Inflammatory Response Syndrome: A Retrospective Study

[Scientific Reports] The authors expored the efficacy and safety of sivelestat (SV) in the treatment of severe acute pancreatitis (SAP) with systemic inflammatory response syndrome. Although SV did not reduce the mortality of patients with SAP, it reduced the length of ventilator use and ICU stay.

Pancreatic Cell News highlights recent top articles in the field of pancreatic cell research. These articles have been carefully selected from high-impact, peer-reviewed academic journals by our experienced editorial team. We cover topics including pancreatic cell culture, pancreatitis, diabetes, and pancreatic cancer. We also feature the latest industry and policy news alongside job postings and upcoming events to keep scientists current while saving them valuable time.

spot_img